healthtalk Arkiv - NHTA

No withdrawals, so far, from Norway’s cancer tender as a result of MFN

NHTA — Tue, 13 Oct 2026 08:09:00 +0000

No suppliers have withdrawn from Norway’s upcoming cancer tender because of U.S. MFN policy.

Sykehusinnkjøp says that, so far, no bidder has communicated a decision to withdraw from the cancer tender due to the U.S. “most favoured nation” policy. The tender will take effect on 1 October 2026.

The agency nevertheless describes the situation as uncertain. It has not discussed MFN with pharmaceutical companies’ headquarters, although some local company representatives have said they cannot rule out future changes without specifying them.

Current status:

Sykehusinnkjøp is working with Nordic counterparts and engaging with companies and other procurement organisations.
U.S. authorities set out in May 2025 an aim to link U.S. medicine prices to the lowest prices in comparable wealthy OECD countries.
AstraZeneca has said there is a risk that Norway could be deprioritised for launches, while stating it had not decided to delay or forgo Norwegian launches.

How the policy may affect future access to new medicines remains unresolved.

Indlægget No withdrawals, so far, from Norway’s cancer tender as a result of MFN blev først udgivet på NHTA.

These are the winners and losers in Norway’s cancer drug tender

NHTA — Fri, 18 Sep 2026 08:24:00 +0000

Norway’s new cancer drug tender rankings take effect on 1 October 2026.

The CEOs of the regional health authorities have decided that the recommendations will apply as instructions in their health trusts. The tender, administered by Sykehusinnkjøp HF, is valued at around three billion NOK and runs until 30 September 2027.

Selected changes:

Tevimbra becomes first choice in several lung cancer settings and ranks ahead of Loqtorzi in nasopharyngeal cancer.
In extensive-stage small-cell lung cancer, Tevimbra plus chemotherapy replaces the two Tecentriq formulations, which are no longer listed for this treatment.
Tecentriq retains first choice in selected NSCLC settings and first-line triple-negative breast cancer with chemotherapy.
Opdivo moves from first to second place around surgery for high-risk non-small-cell lung cancer.
Keytruda remains behind Tecentriq and Libtayo in first-line metastatic non-small-cell lung cancer with high PD-L1 expression.
Calquence plus Venclyxto ranks ahead of Imbruvica plus Venclyxto in previously untreated chronic lymphocytic leukaemia.

Indlægget These are the winners and losers in Norway’s cancer drug tender blev først udgivet på NHTA.